Related Experiment Video
Updated: Nov 18, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
Autologous stem cell transplantation in scleroderma
Dominique Farge1, Nassim Ait Abdallah2, Zora Marjanovic3
1Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Internal Medicine (UF04), MATHEC, Centre of reference for rare systemic autoimmune diseases (FAI2R); Université de Paris, EA 3518, Paris, France; McGill university, department of medicine, Montreal, QC, Canada.
Abstract:
Patients with severe rapidly progressive systemic sclerosis (SSc) have a poor prognosis. Standard immunosuppressive therapies may have modest effects on stabilizing disease, but they fail to improve overall survival. Hematopoietic stem cell transplant (HSCT) is the first treatment to induce disease-modifying therapeutic benefits in rapidly progressive SSc patients. HSCT in rapidly progressive SSc can induce regression of fibrosis in skin and lung, and increase survival. Initially, HSCT was associated with high treatment-related mortality rates. Improvements in patient screening, a better understanding of the risks associated with different treatment regimens, and centre experience have improved the AHSCT safety profile for patients with scleroderma.
More Related Videos
10:30Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications
Published on: December 8, 2016
11:31Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate
Published on: October 31, 2012
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Clinical Applications of Epidermal Stem Cells
iPS Cell Differentiation
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Induced Pluripotent Stem Cells
Somatic...